Apyx Medical Future Growth
Future criteria checks 0/6
Apyx Medical is forecast to grow earnings and revenue by 32% and 7.7% per annum respectively while EPS is expected to grow by 35% per annum.
Key information
32.0%
Earnings growth rate
35.0%
EPS growth rate
Medical Equipment earnings growth | 17.0% |
Revenue growth rate | 7.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Dec 19Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Nov 23Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Sep 14Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 52 | -14 | -5 | N/A | 4 |
12/31/2025 | 48 | -17 | -13 | N/A | 4 |
12/31/2024 | 47 | -25 | -20 | N/A | 4 |
9/30/2024 | 49 | -28 | -18 | -17 | N/A |
6/30/2024 | 49 | -28 | -10 | -9 | N/A |
3/31/2024 | 50 | -23 | -10 | -10 | N/A |
12/31/2023 | 52 | -19 | -6 | -5 | N/A |
9/30/2023 | 50 | -15 | -8 | -8 | N/A |
6/30/2023 | 47 | -16 | -17 | -17 | N/A |
3/31/2023 | 44 | -21 | -18 | -18 | N/A |
12/31/2022 | 45 | -23 | -21 | -20 | N/A |
9/30/2022 | 49 | -19 | -17 | -16 | N/A |
6/30/2022 | 51 | -18 | -15 | -14 | N/A |
3/31/2022 | 52 | -16 | -14 | -13 | N/A |
12/31/2021 | 49 | -15 | -11 | -10 | N/A |
9/30/2021 | 43 | -15 | -12 | -12 | N/A |
6/30/2021 | 38 | -14 | -11 | -11 | N/A |
3/31/2021 | 31 | -15 | -11 | -11 | N/A |
12/31/2020 | 28 | -12 | -17 | -16 | N/A |
9/30/2020 | 25 | -16 | -19 | -18 | N/A |
6/30/2020 | 25 | -16 | -21 | -20 | N/A |
3/31/2020 | 28 | -16 | -22 | -21 | N/A |
12/31/2019 | 28 | -20 | -20 | -18 | N/A |
9/30/2019 | 26 | -18 | -35 | -33 | N/A |
6/30/2019 | 22 | -15 | -30 | -30 | N/A |
3/31/2019 | 19 | -14 | -25 | -25 | N/A |
12/31/2018 | 17 | -11 | -21 | -21 | N/A |
9/30/2018 | 14 | -10 | -2 | -2 | N/A |
6/30/2018 | 13 | -12 | N/A | -1 | N/A |
3/31/2018 | 5 | -15 | N/A | -2 | N/A |
12/31/2017 | 10 | -14 | N/A | -4 | N/A |
9/30/2017 | -12 | -19 | N/A | -5 | N/A |
6/30/2017 | -4 | -17 | N/A | -4 | N/A |
3/31/2017 | 37 | -4 | N/A | -3 | N/A |
12/31/2016 | 9 | -12 | N/A | -3 | N/A |
9/30/2016 | 35 | -5 | N/A | -3 | N/A |
6/30/2016 | 33 | -5 | N/A | -4 | N/A |
3/31/2016 | 31 | -6 | N/A | -6 | N/A |
12/31/2015 | 30 | 8 | N/A | -6 | N/A |
9/30/2015 | 29 | 4 | N/A | -5 | N/A |
6/30/2015 | 28 | 3 | N/A | -3 | N/A |
3/31/2015 | 27 | 4 | N/A | -1 | N/A |
12/31/2014 | 28 | -18 | N/A | 0 | N/A |
9/30/2014 | 26 | -18 | N/A | -2 | N/A |
6/30/2014 | 25 | -15 | N/A | -3 | N/A |
3/31/2014 | 24 | -16 | N/A | -3 | N/A |
12/31/2013 | 24 | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APYX's revenue (7.7% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: APYX's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 08:52 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apyx Medical Corporation is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sam Eiber | BTIG |
Matthew Hewitt | Craig-Hallum Capital Group LLC |
David Turkaly | JMP Securities |